SEC Form 4 · accession 0000899243-15-005030
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Harshbarger
Officer — General Counsel and Secretary
Period of report
Sep 17, 2015
Accepted (ET)
Sep 18, 2015 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Sep 17, 2015 | A | 4,924 | A | — | — | Common Stock | 4,924 | 4,924 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2Subject to the Reporting Person's continued employment with the Issuer, the restricted stock units will vest and become exercisable as to 33.34% of the units on September 17, 2016; 33.33% of the units on September 17, 2017; and 33.33% of the units on September 17, 2018.